- Schizophrenia:
- 1st episode <65 years: Initially PO 1mg/day divided OD/BD then increased by 0.5mg/day every 6-7 days to target 2mg/day
- Max: 16mg/day
- 1st episode <65 years: Initially PO 1mg/day divided OD/BD then increased by 0.5mg/day every 6-7 days to target 2mg/day
-
- Maintenance <65 years: Initially PO 1-2mg/day divided OD/BD, then increased by 0.5mg/day every 3-7 days to target 4mg/day
- Max: 16mg/day
- Maintenance <65 years: Initially PO 1-2mg/day divided OD/BD, then increased by 0.5mg/day every 3-7 days to target 4mg/day
-
- ≥65 years: Initially PO 25mg OD then increase by 0.25-0.5mg/day every 6-7 days to target 2mg/day
- Max: 16 mg/day
- ≥65 years: Initially PO 25mg OD then increase by 0.25-0.5mg/day every 6-7 days to target 2mg/day
-
- 13-17 years: Initially PO 0.5mg OD, then increased by 0.5mg/day every 3-7 days to target 3mg/day
- Max: 6mg/day
- 13-17 years: Initially PO 0.5mg OD, then increased by 0.5mg/day every 3-7 days to target 3mg/day
- Acute manic/mixed bipolar I disorder:
- Adults: PO 2-3mg OD then may adjust dose by 1mg/day no more frequently than every 24 hours
- Max: 6mg/day
- Adults: PO 2-3mg OD then may adjust dose by 1mg/day no more frequently than every 24 hours
-
- 10-17 years: PO 0.5mg OD, then increased by 0.5-1mg/day no more frequently than every 24 hours to target 2.5mg/day
- Max: 6mg/day
- 10-17 years: PO 0.5mg OD, then increased by 0.5-1mg/day no more frequently than every 24 hours to target 2.5mg/day
- Tourette syndrome (Off-label):
- PO 0.5-1mg/day
- May be increased or decreased in increments of 0.5mg BD at intervals >3 days
- Not to exceed 6 mg/day
- Post-traumatic stress disorder (Off-label):
- PO 0.5-8mg/day
- Tablet:
- 1mg
- 2mg
- 3mg
- 4mg
Taken without regard to meals
2nd generation antipsychotic
The exact mechanism is unknown but it is thought to antagonize dopamine D2 receptors, serotonin 5-HT2, alpha1-adrenergic, alpha2-adrenergic and histaminergic receptors
- Somnolence
- Insomnia
- Agitation
- Anxiety
- Headache
- Rhinitis
- Fatigue
- Parkinsonism
- Akathisia
- Increased appetite
- Vomiting
- Drooling
- Urinary incontinence
- Tremor
- Nasopharyngitis
- Rhinorrhea
- Enuresis
- Hypersensitivity to class/components
WARNING
Not approved for dementia-related psychosis
- Amisulpride
Drug Status
| Availability | Prescription only |
| Pregnancy | Weigh risk vs benefit |
| Breastfeeding | Weigh risk vs benefit |
| Schedule | Controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Column 1 Value | Column 2 Value | Column 3 Value | Column 4 Value | Column 5 Value | Column 6 Value |